Navigation Links
Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogen's MGB Probe Technology

First microRNA-based Diagnostic Tests are Expected to be Launched in 2008

and Will Incorporate Nanogen's MGB Probe Technology Rosetta Genomics Will use the Licensed Technology in its Custom Designed Real-Time PCR Diagnostic Assays That Allow for Sensitive Detection and

Quantification of microRNA in Tissues and Body Fluids

REHOVOT, Israel; NORTH BRUNSWICK, New Jersey, December 11 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today it has selected the technological platform for its line of microRNA-based diagnostic products, the first of which are expected to launch in 2008. The company has licensed the MGB Probe technology from Nanogen, Inc. (NASDAQ: NGEN). The licensing deal will allow Rosetta Genomics to combine the technical performance advantages of Nanogen's MGB Probe technology with the Company's own proprietary microRNA biomarkers to create a line of quantitative real-time PCR diagnostic tests.

Leveraging microRNAs' strong tissue specificity and involvement in the regulation of a large number of human genes, Rosetta Genomics has identified specific microRNA signatures that it believes will allow for accurate diagnosis of various cancers.

The Company expects the following three tests to launch in 2008:

- Differentiating squamous from non squamous lung cancer - As current targeted therapy for lung cancer can cause hemorrhaging in squamous cell lung cancer patients, differentiating between the cancer types is critical. Rosetta Genomics has identified several microRNA biomarkers that may allow for sensitive and specific identification of squamous cell carcinoma.

- Differentiating mesothelioma from lung adenocarcinoma - Rosetta Genomics has identified a panel of microRNA biomarkers potentially allowing for differentiation between these cancer types.

Cancer of Unknown Primary (CUP) - This test is designed to assist clinicians to accurately identify the origin of metastases. In 3%-5% of all cancer patients, clinicians cannot identify the origin of a patients' tumor. This information is crucial for determining treatment type. Rosetta Genomics has developed a panel of microRNA biomarkers potentially able to identify approximately thirty cancers

"Our proprietary microRNA detection and quantitation technologies are at the heart of our sensitive diagnostic products," noted Amir Avniel, President and CEO of Rosetta Genomics." Using very small amounts of tissue samples or body fluids, we are able to detect microRNAs on the order of single molecules, as well as differentiate microRNAs with only a single nucleotide mismatch. We look forward to the launch of our first diagnostic products in 2008."

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs.

The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease, and the timing of launch of Rosetta's first diagnostic products constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.



Alan Zachary

T: +1-312-944-6784


Juliane Snowden

T: +1-212-213-0006

SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
9. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. ( Announces Upcoming Interview With CEO of DNAPrint Genomics
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... metabolism. But unless it is bound to proteins, copper is also toxic to ... researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... This ... entrepreneurs at competitive events in five states to develop and pitch their BIG ideas ... projects from each state are competing for votes to win the title of SAP's ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) ... remaining 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) ... B Warrants") subject to the previously disclosed November ... 2015, which will result in the issuance of ... the issuance of such shares, there will be ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences ... today that Mr. Pierre Laurin , President and Chief ... at the upcoming Piper Jaffray 27 th Annual Healthcare ... on December 1-2, 2015. st , at ... one-on-one meetings throughout the day. The presentation will be available ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that it has been selected ... of only three finalists for a 2015 Tekne ... category. The Tekne Awards honor Minnesota ... and leadership. iMedNet™ eClinical  technology ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
Breaking Biology News(10 mins):